|Bid||0.00 x 1400|
|Ask||0.00 x 3000|
|Day's Range||91.39 - 92.83|
|52 Week Range||78.74 - 96.06|
|PE Ratio (TTM)||N/A|
|Beta (3Y Monthly)||0.93|
|Expense Ratio (net)||0.14%|
Pfizer (PFE) reported revenue growth in international markets during the second quarter. Lower sales from US markets offset the growth during the quarter.
Health Care Select Sector SPDR stood out among the best ETFs as it was the only of 28 members of IBD's ETF Leaders screen trading above its 50-day moving average.
Strong earnings results from healthcare giants are supporting a rally in the defensive sector-related exchange traded funds. On Tuesday, the Health Care Select Sector SPDR (NYSEArca: XLV) gained 2.5%. ...
A popular way to bet on the health-care sector, the Health Care Select Sector SPDR ETF , Tuesday afternoon was on track for its best daily gain since November of 2016. The exchange-traded fund was up 2.2% in afternoon action, putting it on pace for its sharpest single-session rise since a 3.4% surge on Nov. 9, according to Dow Jones Market Data. That was the day after Trump was elected. Tuesday's moves for the so-called "XLV" fund, a reference to its ticker symbol, is supported by a jump in shares of UnitedHealth Group Inc. , which posted better-than-expected quarterly results before the official start of trading, along with Johnson & Johnson . Gains in health-care were helping to lift the broader market (along with information technology), with the Dow Jones Industrial Average gaining more than 400 points or 1.6%, the S&P 500 index up by 1.6% and the Nasdaq Composite Index advancing by 2.2%.
All of the S&P 500 index sectors on Tuesday were trading in positive territory, and 10 of those sectors boast gains of at least 1%, led by 2.3% surge in the information technology sector. The S&P 500 index was up 1.6% at 2,794, trading at around session highs, with the tech sector up 2.5%, and health-care stocks rallying by 2.2%. The tech-heavy Nasdaq Composite Index , meanwhile, was up 2.1% at 7,589 and the Dow Jones Industrial Average climbed by more than 400 points or 1.6% at 25,656. A day earlier technology and internet-related shares led U.S. stocks to modest losses. On Tuesday, Wall Street stocks, after a mostly downbeat stretch for equity benchmarks, were rising on the back of a strong round of quarterly corporate resulst from banks Goldman Sachs Group Inc. , Morgan Stanley , and health-care names UnitedHealth Group Inc. and Johnson & Johnson .
With seasonal volatility, rising interest rates, uncertainty over a tariff war with China and fast-approaching mid-term elections all on the minds of investors, the best ETFs to buy now are those that invest in defensive areas of the market.
In the first quarter of fiscal 2019, Medtronic generated net revenues of $7.4 billion, a ~0.1% year-over-year (or YoY) decline. Wall Street analysts estimate that Medtronic will generate revenues of $7.3 billion in the second quarter of fiscal 2019.
Pfizer Inc. will pay over $700,000 to settle charges for "deceptive advertising," according to a statement from New York Attorney General Barbara Underwood. Pfizer's stock dropped 2.7% in morning trade, enough to pace the Dow Jones Industrial Average's decliners. Pfizer's payment includes over $200,000 in restitution for New York consumers and $500,000 in penalties, feels and costs. The company had promised consumers they would pay no more than a $15 to $20 for certain drugs, but many ended up spending far more than that. The stock was still up 16.5% over the past three months, while the SPDR Health Care Select Sector ETF has gained 5.8% and the Dow has tacked on 3.2%.
On October 10, Abbott Laboratories (ABT) ended the trading day at $68.92, down ~3.3% from the previous day’s close. On the day, Morgan Stanley raised its target price on ABT stock from $70 to $80. However, the stock price dropped as the broader market sell-off pulled down ABT stock prices along with a large number of other healthcare stocks. The SPDR S&P 500 ETF (SPY) was down ~3.2% on October 10.
Yesterday, most healthcare stocks were trading below their previous day’s closing price. Biotech players seem to have been hit the worst. However, all other sectors including pharmaceuticals, medical devices, and hospitals saw significant weakness. Johnson & Johnson (JNJ), Boston Scientific (BSX), Pfizer (PFE), Merck (MRK), and Bristol-Myers Squibb fell 1.1%, 2.1%, 2.6%, and 3.9%, respectively, yesterday. Major biotechnology players Gilead Sciences (GILD), Amgen (AMGN), Biogen (BIIB), and Novo Nordisk (NVO) fell 2.30%, 2.33%, 2.04%, and 1.81%, respectively.
The healthcare industry is watching the Trump presidency closely. President Trump's promise to repeal and replace Obamacare hit repeated stumbling blocks in Congress. Despite the uncertainty surrounding these efforts to overhaul the nation's healthcare system, a number of healthcare stocks rose dramatically throughout 2017.
The Department of Justice issued a preliminary approval for CVS Pharmacy to acquire health care insurance company Aetna, possibly paving the way for transformative changes in the industry as cries for more affordable care emanating from consumers and regulators get louder. The Health Care Select Sector SPDR ETF (XLV) slid 0.42% as of 11:45 a.m. ET, Vanguard Health Care ETF (VHT) fell 0.54%, iShares US Medical Devices ETF (IHI) was down 1.21%, and iShares US Healthcare ETF (IYH) slid 0.55%. As part of the approval process, the DOJ set forth the condition that Aetna had to divest itself from its Medicare Part D drug plan, which it eventually sold to WellCare Health Plans for an undisclosed amount late last month.
Wall Street analysts expect Celgene to report a net income and EPS of $1.2 billion and $1.71, respectively, in the third quarter.
Shares of Mylan N.V. dropped 1.4% toward a one-year low in afternoon trade Tuesday, after the drug maker was downgraded at Morgan Stanley on concerns over generic sales trends, risks to EpiPen from generic competition and biosimilars strategy that's less compelling that expected. Analyst David Risinger cut his rating to equal weight, saying his thesis for upgrading the stock to overweight in March is now "broken." He lowered his stock price target to $36, which is 3.1% above current levels, from $42. Back in March 2018 when we upgraded [Mylan] from EW to OW, we expected solid growth prospects versus peers, differentiated pipeline progress and positive catalysts," Risinger wrote in a note to clients. "But newsflow has disappointed, and we fear further pressure even though we still expect Mylan to receive FDA approval of its generic Advair imminently." The stock has shed 17.7% year to date, while the SPDR Health Care Select Sector ETF has rallied 14.5% and the S&P 500 has gained 8.0%.
On October 3, Allergan’s (AGN) stock price closed at $193.46, which is ~11.0% below its 52-week high of $215.10 on October 3, 2017. Allergan’s stock price grew from $164.05 at the open of the market on January 2 to $193.46 on October 3, which reflects ~18.0% YTD (year-to-date) growth. On March 5, Merck hit its 52-week low of $142.81.
The Health Care Select Sector SPDR (XLV) , the largest healthcare exchange traded fund by assets, and rival healthcare ETFs have spent much of 2018 in rally mode, but that is not stopping some traders from betting on a near-term pullback for the high-flying sector. XLV allocates about two-thirds of its combined weight to pharmaceuticals and biotechnology stocks. There are other catalysts to consider, including that the U.S. economy is moving into the late-cycle phase, overall growth may slow and signs of an economic slowdown could pop up.
The US jobs report for September was released on October 5. While the jobs report was mixed, there were enough signs that the labor market was tightening, which would eventually lead to wage growth gains.
Economists expect the US economy to add 180,000 jobs in September—below the 201,000 job additions reported in August and the average monthly gain of 196,000 over the previous 12 months. Economists’ estimate for job additions could have an upside, according to data from ADP and Moody’s Analytics. Based on the data released on October 3, private companies added 230,000 more jobs in September—much higher than the expectations of 184,000 jobs. The job additions were the highest level since 241,000 job additions in February.
Shares of Eli Lilly & Co. rallied 3.1% toward a record high in premarket trade Thursday, after drugmaker announced positive results from a trial of its diabetes treatment. The company said a phase 2b trial of dual GIP and GLP-1 receptor agonist showed "strong and clinically meaningful blood sugar reduction and weight loss" in people with type 2 diabetes. "These phase 2b clinical trial results for GIP/GLP-1 RA are unprecedented, and the impressive blood glucose and weight reductions seen may lead to a new treatment option for people with type 2 diabetes," said Juan Frias, principal investigator at the National Research Institute. Separately, Lilly and Boehringer Ingelheim said a phase 3 trial of its type 1 diabetes treatment met its primary endpoint. Lilly's stock has soared 25.6% over the past three months, while the SPDR Health Care Select Sector ETF has climbed 13.6% and the Dow Jones Industrial Average has gained 11.0%.
Health care stocks posted major gains in the latest quarter, leaving many other sectors in the dust. Performance like that has propelled the S&P 500 health care ETF ( XLV) upward by 13% year-to-date (YTD) through Monday's close, compared to the broader S&P 500's 9.4% return over the same period, as industry players such as Biogen Inc. ( BIIB), Eli Lilly and Co. ( LLY) and Pfizer Inc. ( PFE) drive the sector's outperformance. Healthcare bulls expect electoral results to favor the outlook for policies beneficial to a wide range of healthcare related companies.
The closing price for Mylan (MYL) stock on September 25 was $23.27, and its market capitalization stood at $19.4 billion. The stock registered its 52-week high of $47.82 on January 23 and its 52-week low of $30.73 on September 28. Currently, Mylan stock is trading above its 50-day moving average of $23.18 as well as its 200-day moving average of $21.39.
Healthcare stocks have been on fire recently, with the SPDR Healthcare Select Sector ETF surging nearly 15 percent over the past 3 months alone.